ClinicalTrials.gg
CompletedNCT03327623Updated Mar 26, 2025

Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)

An observational study in Hypertrophic Cardiomyopathy, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Mayo Clinic · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
290
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies in Cardiomyopathy, Hypertrophic with a site in United States — 23 open to participants now, 37 under way, 6 of them phase 3. Cardiomyopathy, Hypertrophic · United States.

Enrollment
17th of 58
290 · median 150
Started
2017
with 2 others
Observational
60 of 125
11 open now
Registered
60th of 125
by date
Lead sponsor
5 of 125
Mayo Clinic

Among the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States, this one is the 17th largest by enrollment of the 58 observational ones that give a count, is one of 3 that started in 2017, is one of 60 observational ones, and was the 60th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

23 of the 125 studies in Cardiomyopathy, Hypertrophic with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Cardiomyopathy, Hypertrophic with a site in United States, or all of them as a file.
02

Study summary

The investigators are trying to find out how common sleep apnea is in hypertrophic cardiomyopathy. The purpose of this study is to see if sleep apnea is common in hypertrophic cardiomyopathy and if its presence is associated with changes in the functioning of the body. The investigators want to determine if sleep apnea is associated with electrical disorders of the heart in patients with hypertrophic cardiomyopathy.

Read the detailed description

Participants will be healthy volunteers or subjects with the diagnosis of hypertrophic cardiomyopathy (HCM). All patients will a undergo a one time; medical history, physical examination, questionnaires, sleep observation in hospital, blood and urine samples, ultrasound scan of the heart, paced breathing test, ultrasound of brachial artery in the arm, MRI of the heart \& 48 hour ECG Holter monitoring. Comparison between the normal volunteers and subjects with HCM will be made.

03

Conditions studied

  • Hypertrophic Cardiomyopathy

Keywords

  • sleep apnea
  • arrhythmia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers and Subjects from The Mayo Clinic Hypertrophic Cardiomyopathy (HCM) Registry who reside in Minnesota.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with a diagnosis of HCM
  • Able to consent
  • Non-pregnant
  • Healthy Controls free of hypertrophic cardiomyopathy and without a definitive family history of hypertrophic cardiomyopathy.

Exclusion criteria

Exclusion criteria:

  • Decompensated Heart failure at time of enrollment (prior history of HF is not an exclusion criteria)
  • Severe (known) (COPD) ( between 30 and 50 percent of normal)
  • Vulnerable study populations except for minorities (minorities may be targeted to achieve 25% minority recruitment required by the NIH)
  • Pregnant women
  • Children
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
290 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hypertrophic Cardiomyopathy (HCM)

    Subjects with a diagnosis of Hypertrophic Cardiomyopathy

  • Control

    Subjects who are healthy volunteers

06

What researchers measure

Primary outcomes

  1. Prevalence of Obstructive Sleep Apnea (OSA).

    Measured by the Apnea-hypopnea index (AHI). The AHI is the number of apneas or hypopneas recorded during the study per hour of sleep. It is generally expressed as the number of events per hour. Based on the AHI, sleep apnea is diagnosed if an AHI ≥5 events/hour.

    Time frame: Approximately 2 years.

  2. Determine the severity of Sleep Apnea.

    The severity of OSA is classified based on the AHI as follows: None/Minimal: AHI \< 5 per hour, Mild: AHI ≥ 5, but \< 15 per hour, Moderate: AHI ≥ 15, but \< 30 per hour, Severe: AHI ≥ 30 per hour.

    Time frame: Approximately 2 years.

  3. Differences in Autonomic Regulation.

    In persons with hypertrophic cardiomyopathy and sleep apnea vs. those without sleep apnea.

    Time frame: Approximately 2 years.

  4. Prevalence of atrial arrhythmias.

    Investigators will determine prevalence of atrial arrhythmias, based on prior ECG documented atrial arrhythmias at any timepoint prior to enrolment and up to 4 weeks after the study date. Participants will also have a 48h ECG (extended Holter) recorder attached to screen for atrial arrhythmias.

    Time frame: Approximately 2 years.

  5. Incidence of atrial arrhythmias.

    Time frame: Approximately 5 years.

  6. Frequency of ventricular arrhythmias.

    Investigators will prospectively follow patients with hypertrophic cardiomyopathy to determine the frequency of ventricular arrhythmias in those with vs those without sleep apnea.

    Time frame: Approximately 5 years.

Secondary outcomes

  1. Identify novel biomarkers

    Participants will be prospectively followed and blood collected to identify biomarkers of arrhythmia, heart failure and prognosis in persons with hypertrophic cardiomyopathy.

    Time frame: Approximately 5 years

  2. Investigate the association of sleep apnea with atrial and ventricular fibrosis

    Participants will undergo baseline MRI studies of the heart to determine the burden of fibrosis and its association with sleep apnea. Participants may be invited to complete a follow-up study to track changes in fibrosis.

    Time frame: Approximately 7 years

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2024, 79 months.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's 79 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2017
First posted
Oct 31, 2017
StartActual
Nov 13, 2017
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03327623
Lead sponsor
Mayo Clinic
Responsible party
Virend Somers, MD, PhD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 31, 2017
Start date
Nov 13, 2017
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Last update
Mar 26, 2025

Study contacts

Virend Somers, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion